Cargando…
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myoca...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533049/ https://www.ncbi.nlm.nih.gov/pubmed/23204139 http://dx.doi.org/10.1136/bmjopen-2012-001925 |
_version_ | 1782254382870429696 |
---|---|
author | Preiss, David Thomas, Laine E Sun, Jie-Lena Haffner, Steven M Holman, Rury R Standl, Eberhard Leiter, Lawrence A Mazzone, Theodore Rutten, Guy E Tognoni, Gianni Martinez, Felipe A Chiang, Fu-Tien Califf, Robert M McMurray, John J |
author_facet | Preiss, David Thomas, Laine E Sun, Jie-Lena Haffner, Steven M Holman, Rury R Standl, Eberhard Leiter, Lawrence A Mazzone, Theodore Rutten, Guy E Tognoni, Gianni Martinez, Felipe A Chiang, Fu-Tien Califf, Robert M McMurray, John J |
author_sort | Preiss, David |
collection | PubMed |
description | OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. DESIGN: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. SETTING: Clinical trial participants in 40 countries. PARTICIPANTS: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. PRIMARY AND SECONDARY OUTCOME MEASURES: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. RESULTS: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. CONCLUSIONS: The most powerful independent predictors of cardiovascular events in IGT included both established risk factors and other variables excluding measures of glycaemia, allowing effective identification of high-risk individuals. |
format | Online Article Text |
id | pubmed-3533049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-35330492013-01-04 Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial Preiss, David Thomas, Laine E Sun, Jie-Lena Haffner, Steven M Holman, Rury R Standl, Eberhard Leiter, Lawrence A Mazzone, Theodore Rutten, Guy E Tognoni, Gianni Martinez, Felipe A Chiang, Fu-Tien Califf, Robert M McMurray, John J BMJ Open Cardiovascular Medicine OBJECTIVES: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. DESIGN: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. SETTING: Clinical trial participants in 40 countries. PARTICIPANTS: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. PRIMARY AND SECONDARY OUTCOME MEASURES: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. RESULTS: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. CONCLUSIONS: The most powerful independent predictors of cardiovascular events in IGT included both established risk factors and other variables excluding measures of glycaemia, allowing effective identification of high-risk individuals. BMJ Publishing Group 2012-12-01 /pmc/articles/PMC3533049/ /pubmed/23204139 http://dx.doi.org/10.1136/bmjopen-2012-001925 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Cardiovascular Medicine Preiss, David Thomas, Laine E Sun, Jie-Lena Haffner, Steven M Holman, Rury R Standl, Eberhard Leiter, Lawrence A Mazzone, Theodore Rutten, Guy E Tognoni, Gianni Martinez, Felipe A Chiang, Fu-Tien Califf, Robert M McMurray, John J Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title_full | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title_fullStr | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title_full_unstemmed | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title_short | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
title_sort | predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (navigator) trial |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533049/ https://www.ncbi.nlm.nih.gov/pubmed/23204139 http://dx.doi.org/10.1136/bmjopen-2012-001925 |
work_keys_str_mv | AT preissdavid predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT thomaslainee predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT sunjielena predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT haffnerstevenm predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT holmanruryr predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT standleberhard predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT leiterlawrencea predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT mazzonetheodore predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT ruttenguye predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT tognonigianni predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT martinezfelipea predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT chiangfutien predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT califfrobertm predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT mcmurrayjohnj predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial |